Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Classical hematology 1

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 3beta-Thalassemia 1Primary Myelofibrosis 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Anemia 1

Interventions

fludarabine 32Specimen Handling 30Cyclophosphamide 28Azacitidine 28venetoclax 27Biopsy 24fludarabine phosphate 23ruxolitinib 18Whole-Body Irradiation 18Cytarabine 18Busulfan 18Mycophenolic Acid 17Tacrolimus 16asciminib 15Melphalan 14Injections 13Decitabine 13decitabine and cedazuridine drug combination 11X-Rays 11Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Sirolimus 10Peripheral Blood Stem Cell Transplantation 10Cyclosporine 10Thiotepa 9Filgrastim 8nilotinib 7Methotrexate 7Imatinib Mesylate 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
luspatercept × Myeloid × 90 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡